{"id":55,"date":"2019-09-02T09:43:42","date_gmt":"2019-09-02T09:43:42","guid":{"rendered":"https:\/\/xspraypharma.com\/?page_id=55"},"modified":"2025-09-08T14:31:03","modified_gmt":"2025-09-08T14:31:03","slug":"affarsmodell","status":"publish","type":"page","link":"https:\/\/xspraypharma.com\/sv\/affarsmodell\/","title":{"rendered":"Aff\u00e4rsmodell"},"content":{"rendered":"<section class=\"block content-block\">\n\t\t\t\t\t\t<div class=\"container-fluid container-small editor_content\">\n\t\t\t\t<h2>Unik teknologi &#8211; unik aff\u00e4rsmodell<\/h2>\n<p><strong>Xspray Pharma AB <\/strong>\u00e4r ett l\u00e4kemedelsbolag som har flera produktkandidater i klinisk utvecklingsfas. Xspray Pharma anv\u00e4nder sin innovativa patenterade teknologi f\u00f6r att utveckla amorfa produktkandidater som \u00e4r f\u00f6rb\u00e4ttrade versioner av marknadsf\u00f6rda l\u00e4kemedel, i f\u00f6rsta hand proteinkinash\u00e4mmare (PKI:er) f\u00f6r behandling av cancer. Ofta har originalbolagen sekund\u00e4ra patent som baseras p\u00e5 kristallina former av den aktiva substansen. Tack vare att Xspray Pharmas produkter \u00e4r amorfa kan de marknadsf\u00f6ras direkt efter att originalbolagens substanspatent g\u00e5r ut. \u00c4ven efter att ett<br \/>\noriginall\u00e4kemedels sekund\u00e4ra patent l\u00f6per ut har Xspray Pharmas produktkandidater kvar sina profilf\u00f6rdelar som gynnar patienter, j\u00e4mf\u00f6rt med generika som helt efterliknar originall\u00e4kemedlet. Det inneb\u00e4r en unik m\u00f6jlighet f\u00f6r en gynnsam marknadsetablering med begr\u00e4nsad konkurrens p\u00e5 en m\u00e5ngmiljardmarknad.<\/p>\n<p>PKI-l\u00e4kemedel utg\u00f6r det st\u00f6rsta segmentet f\u00f6r riktade cancerbehandlingar d\u00e4r f\u00f6rs\u00e4ljningen uppg\u00e5r till cirka 37 procent av den totala onkologimarknaden och med \u00e5rligen \u00f6kande f\u00f6rs\u00e4ljningssiffror. 2021 uppgick f\u00f6rs\u00e4ljningen av PKI-l\u00e4kemedel p\u00e5 den amerikanska marknaden till cirka USD 33 miljarder.<\/p>\n<p>Efterfr\u00e5gan p\u00e5 effektiva livscykelprodukter \u00f6kar i takt med att patenten f\u00f6r m\u00e5nga viktiga originall\u00e4kemedel f\u00f6rfaller. F\u00f6r de 80 PKI:er som idag \u00e4r marknadsf\u00f6rda i USA f\u00f6rv\u00e4ntas 23 substanspatent f\u00f6rfalla t.o.m. \u00e5r 2030. Xspray Pharma har hittills testat sin teknologi p\u00e5 ett tjugotal av USA-marknadens etablerade PKI:er med goda resultat.<\/p>\n\t\t\t<\/div>\n\t\t\t<\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-55","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Aff\u00e4rsmodell - Xspray<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/xspraypharma.com\/sv\/affarsmodell\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aff\u00e4rsmodell - Xspray\" \/>\n<meta property=\"og:url\" content=\"https:\/\/xspraypharma.com\/sv\/affarsmodell\/\" \/>\n<meta property=\"og:site_name\" content=\"Xspray\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-08T14:31:03+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/xspraypharma.com\/sv\/affarsmodell\/\",\"url\":\"https:\/\/xspraypharma.com\/sv\/affarsmodell\/\",\"name\":\"Aff\u00e4rsmodell - Xspray\",\"isPartOf\":{\"@id\":\"https:\/\/xspraypharma.com\/sv\/#website\"},\"datePublished\":\"2019-09-02T09:43:42+00:00\",\"dateModified\":\"2025-09-08T14:31:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/xspraypharma.com\/sv\/affarsmodell\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/xspraypharma.com\/sv\/affarsmodell\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/xspraypharma.com\/sv\/affarsmodell\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/xspraypharma.com\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aff\u00e4rsmodell\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/xspraypharma.com\/sv\/#website\",\"url\":\"https:\/\/xspraypharma.com\/sv\/\",\"name\":\"Xspray\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/xspraypharma.com\/sv\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aff\u00e4rsmodell - Xspray","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/xspraypharma.com\/sv\/affarsmodell\/","og_locale":"sv_SE","og_type":"article","og_title":"Aff\u00e4rsmodell - Xspray","og_url":"https:\/\/xspraypharma.com\/sv\/affarsmodell\/","og_site_name":"Xspray","article_modified_time":"2025-09-08T14:31:03+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/xspraypharma.com\/sv\/affarsmodell\/","url":"https:\/\/xspraypharma.com\/sv\/affarsmodell\/","name":"Aff\u00e4rsmodell - Xspray","isPartOf":{"@id":"https:\/\/xspraypharma.com\/sv\/#website"},"datePublished":"2019-09-02T09:43:42+00:00","dateModified":"2025-09-08T14:31:03+00:00","breadcrumb":{"@id":"https:\/\/xspraypharma.com\/sv\/affarsmodell\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/xspraypharma.com\/sv\/affarsmodell\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/xspraypharma.com\/sv\/affarsmodell\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/xspraypharma.com\/sv\/"},{"@type":"ListItem","position":2,"name":"Aff\u00e4rsmodell"}]},{"@type":"WebSite","@id":"https:\/\/xspraypharma.com\/sv\/#website","url":"https:\/\/xspraypharma.com\/sv\/","name":"Xspray","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/xspraypharma.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/xspraypharma.com\/sv\/wp-json\/wp\/v2\/pages\/55","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xspraypharma.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/xspraypharma.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/xspraypharma.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/xspraypharma.com\/sv\/wp-json\/wp\/v2\/comments?post=55"}],"version-history":[{"count":94,"href":"https:\/\/xspraypharma.com\/sv\/wp-json\/wp\/v2\/pages\/55\/revisions"}],"predecessor-version":[{"id":10998,"href":"https:\/\/xspraypharma.com\/sv\/wp-json\/wp\/v2\/pages\/55\/revisions\/10998"}],"wp:attachment":[{"href":"https:\/\/xspraypharma.com\/sv\/wp-json\/wp\/v2\/media?parent=55"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}